Effectiveness of Anti SARS-CoV-2 Immunizations Through the Quantification of Neutralizing Antibodies 2022-2023

Abstract

Objective: To quantify anti-RBD IgG neutralizing antibodies to measure the effectiveness of immunizations against SARS-CoV-2 (Sinopharm, Sputnik V, Astrazeneca, Pfizer, Johnson&Johnson, Moderna) after the single, second, third and/or 4th dose, depending on corresponds to 90 -180 to 270 days after vaccination.

Methods: Prospective Cohort. In the city of La Paz, population aged 18 to 90, of both sexes, who agreed to participate and who received any of the COVID-19 vaccine schedules, a partial or complete two-dose and/or booster schedule (Sputnik V, Sinopharm, Astrazeneca, Pfizer, Johnson&Johnson, Moderna) at 90-180 up to 270 days after vaccination. Venous blood samples for plasma or serum for determination of Neutralizing Antibodies quantified by the immunochemiluminescence method (MAGLUMI 600), high-performance immunoassay reagents, which detect immunoglobulin G antibodies against SARS-CoV-2 protein S.

Results: The study sample was 531 people. Neutralizing Antibodies (Nab) against COVID-19 disease are data that are known for the first time in a high-altitude population (3600 meters above sea level). The average age is 48 years (n: 312 women), in men it is 50 years (n: 219). The distribution of the number of doses received by the study population: one dose (1.32%), 2 doses (5.29%), 3 doses (34.4%) and 4 doses (58.98%). The type of Vaccine for the first and second dose was the SINOPHARM vaccine (average RBD IgG 595 AU/ ml), third dose ASTRAZENECA vaccine (RBD IgG 664 AU/ml) and 4th. Pfizer dose (average RBD IgG 773 AU/mL). All vaccines have high averages of neutralizing antibodies against SARS-CoV-2.

Conclusions: The vaccines show effectiveness individually and in combination verified with the Ab values. Neutralizers.